GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Net Change in Cash

Joinn Laboratories (China) Co (SHSE:603127) Net Change in Cash : ¥-96 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Joinn Laboratories (China) Co's Net Change in Cash for the three months ended in Mar. 2024 was ¥12 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-96 Mil.

Joinn Laboratories (China) Co Net Change in Cash Historical Data

The historical data trend for Joinn Laboratories (China) Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Net Change in Cash Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.27 128.09 3,845.35 -1,250.93 -45.82

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.68 66.40 -136.28 -37.63 11.67

Joinn Laboratories (China) Co Net Change in Cash Calculation

Joinn Laboratories (China) Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=622.875+-315.429+-361.678+8.41
=-46

Joinn Laboratories (China) Co's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=119.954+-67.562+-37.928+-2.796
=12

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Net Change in Cash
Comparable Companies
SZSE:300676 SZSE:300244 SHSE:603108 SZSE:300406 SZSE:300463 SZSE:300685 SHSE:603882 SZSE:300396 SZSE:300639 SZSE:301060 TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
06127:Hong Kong
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Website
https://www.joinnlabs.com
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yao Da Lin Director
Sun Yun Xia Director
Zuo Cong Lin Director
Gao Da Peng Director
Li Ye Supervisors
Gu Xiao Lei Director
Feng Yu Xia Director
Gu Jing Liang senior management
Yu Ai Shui senior management
Yin Li Li Supervisors
Sun Hui Ye Supervisors
Gu Mei Fang Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines